Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidat
Data Presented During ASN Kidney Week 2023 Demonstrate Significant Reversal of Albuminuria in Chronic Disease ModelFirst-in-Human Trial of MZE829 Development Candidate Anticipated to Begin by End of 2023SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new p...
United States Harold Bernstein Jillian Connell American Society Of Nephrology Kidney Week Data Presented During Significant Reversal
Source: pharmiweb.com